When was Graybug Vision founded?

Graybug Vision was founded in 2011.

Where is Graybug Vision located?

Graybug Vision is headquartered in Redwood City, United States.

Who is the current CEO of Graybug Vision?

Frederic Guerard of Graybug Vision.

How many employees does Graybug Vision have?

As of Jul 01, 2024, the latest employee count at Graybug Vision is 33.

Is Graybug Vision a funded company?

Graybug Vision is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Graybug Vision rank among its competitors?

Graybug Vision ranks 78th amongst 118 active competitors, of which 44 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of Graybug Vision?

Graybug Vision's top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

Graybug Vision - 2026 Company Profile, Team, Competitors & Financials

Graybug Vision is a deadpooled company based in Redwood City (United States), founded in 2011. It operates as a Developer of drugs for treating chronic vision-threatening diseases like retina & cornea disorders. The company has 118 active competitors, including 44 funded and 23 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.

Company Details

Graybug Vision is a developer of drugs for treating chronic vision-threatening diseases like retina & cornea disorders. It has developed a GB-102 drug that is a potent small-molecule multiple receptor tyrosine kinase inhibitor. It is designed to treat chronic vision-threatening diseases such as wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, glaucoma, and others. It is a potent pan-VEGF inhibitor and neuroprotectant that blocks all VEGF receptors associated with angiogenesis, vascular permeability, cellular proliferation, and fibrosis.

Website: graybug.vision
Email ID: *****@graybug.vision
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

Redwood City, United States

Stage

Deadpooled

Ranked

78^th among 118 active competitors

Employee Count

33 as on Jul 01, 2024

Similar Companies

4D Molecular Therapeutics & 122 more

View Graybug Vision's full profile

Graybug Vision is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Graybug Vision, Inc. CIN: 1534133 , United States, Active		-	-	-

Graybug Vision has not raised any funding rounds yet.

Graybug Vision's employee count trend

Graybug Vision has 33 employees as of Jul 24. Here is Graybug Vision's employee count trend over the years:

Uncover Graybug Vision's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Graybug Vision include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Graybug Vision, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	68/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	66/100
5th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Lincoln Park Capital & 8 others	64/100
6th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Atlas Venture, Forbion & 11 others	63/100
7th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Marshall Wace & 10 others	62/100
8th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, Avoro Capital & 12 others	61/100
9th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	61/100
10th	Opus Genetics 2021, Durham (United States), Public	Developer of gene therapies to treat retinal degenerative diseases	$23.5M	RD Fund, Bios Partners & 2 others	59/100
78th	Graybug Vision 2011, Redwood City (United States), Deadpooled	Developer of drugs for treating chronic vision-threatening diseases like retina & cornea disorders	-	-	25/100